Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)
当レポートでは、世界の肝炎ウイルス診断検査の関連市場における、主要なパイプライン製品 (医療機器) とその治験の進行状況について調査すると共に、製品特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (資本取引・事業提携など) といった情報を取りまとめてお届けいたします。
Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Hepatitis C Tests market for the year 2020 and beyond. Hepatitis C is a viral infection caused by hepatitis C virus (HCV). Hepatitis C virus is a blood borne virus that causes liver disease and can cause acute and chronic hepatitis. Infection may be caused through injection drug use, transfusion of unscreened blood products, unsafe injection practices, sexual contact and from infected mother to her baby.
Diagnosis of HCV infection can be done by screening for anti-HCV antibodies along with a serological test to confirm the viral infection. Nucleic acid test for HCV ribonucleic acid (RNA) is performed in case of positive test results for anti HCV antibodies to confirm chronic infection. Since there is no vaccine available for HCV infection, the World Health Organization (WHO) recommends blood tests to screen patients that are at an increased risk of HCV infection and reducing the risk of HCV exposure in health care settings. Screening of pregnant women for HCV is standard of care in most countries and considered to be a cost-effective strategy for reducing the risk of transmission to the baby.
The Hepatitis C virus tests includes Hepatitis C Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis C Nucleic Acid Amplification Tests (NAATs) and Multi-parameter HIV, Hepatitis B, and Hepatitis C Nucleic Acid Amplification Tests (NAATs).
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are -
Currently marketed Hepatitis C Tests and evolving competitive landscape -
Global, Regional and Country level market specific insights -
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered - Abbott Laboratories, Siemens Healthineers AG, Grifols SA, F. Hoffmann-La Roche Ltd, Ortho-Clinical Diagnostics Inc, Hologic Inc, Others
Countries covered - United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
Who should buy this report?
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -